[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344082-105":59,"doc-detail-344082-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","where-are-we-with-gastric-cancer-screening-in-europe-in-2024","Where are we with gastric cancer screening in Europe in 2024?","","The absolute number of annual gastric cancer cases in Europe is increasing while the Council of the European Union recommends launching screening in high-incidence, high-death regions. Yet, as of 2024, no organised gastric cancer screening programme has been implemented across Europe. Evidence supports the screen-and-treat approach targeting Helicobacter pylori, but optimisation is required. Key implementation elements include target age range, test types, eradication regimens, surveillance strategies, and ongoing projects expected to fill evidence gaps.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/where-are-we-with-gastric-cancer-screening-in-europe-in-2024/344082/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/where-are-we-with-gastric-cancer-screening-in-europe-in-2024/344082.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the status of organised gastric cancer screening in Europe in 2024?","Question",{"text":113,"@type":114},"No organised gastric cancer screening programme has been launched across Europe as of 2024.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is Helicobacter pylori screen-and-treat considered promising for Europe?",{"text":118,"@type":114},"The document states that among available strategies, the screen-and-treat approach for H. pylori is the most appropriate for Europe.",{"name":120,"@type":111,"acceptedAnswer":121},"Which organisational aspects must be defined before full implementation?",{"text":122,"@type":114},"Implementation requires defining the target age range, test types, H. pylori eradication regimens, and surveillance strategies, among other screening set-up details.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344082,1790472531,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Recent advances in clinical practice  \nWhere are we with gastric cancer screening in Europe in 2024?  \nMārcis Leja  1,2,3  \n1Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia 2Department of Gastroenterology, Digestive Diseases Centre GASTRO, Riga, Latvia  \n3Department of Research, Riga East University Hospital, Riga, Latvia  \nCorrespondence to  \nDr Mārcis Leja, Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia; [marcis.leja@lu.lv](marcis.leja@lu.lv)  \nReceived 21 April 2024 Accepted 14 August 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nTo cite: Leja M. Gut Epub  \nahead of print: [please include Day Month Year] . doi:10.1136/ gutjnl-2024-332705  \nABSTRACT  \nThe absolute number of annual cases of gastric cancer in Europe is rising. The Council of the European Union has recommended implementation of gastric cancer screening for countries or regions with a high gastric cancer incidence and death rates. However, as of 2024 no organised gastric cancer screening programme has been launched in Europe.  \nThere are several ways to decrease gastric cancer burden, but the screen and treat strategy for Helicobacter pylori (H. pylori) seems to be the most appropriate for Europe. It has to be noted that increased use of antibiotics would be associated with this strategy.  \nOnly organised population-based cancer screening is recommended in the European Union, therefore gastric cancer screening also is expected to fulfil the criteria of an organised screening programme. In this respect, several aspects of screening organisation need to be considered before full implementation of gastric cancer prevention in Europe; the age range of the target group, test types, H. pylori eradication regimens and surveillance strategies are among them. Currently, ongoing projects (GISTAR, EUROHELICAN, TOGAS and EUCanScreen) are expected to provide the missing evidence. Feedback from the decision-makers and the potential target groups, including vulnerable populations, will be important to planning the programme.  \nThis paper provides an overview of the recent decisions of the European authorities, the progress towards gastric cancer implementation in Europe and expected challenges. Finally, a potential algorithm for gastric cancer screening in Europe is proposed.  \nINTRODUCTION  \nUntil a few years ago, the need for prevention of gastric cancer has not been prioritised in the Western world, including Europe, because of declining incidence and mortality indicators.  \nAlthough the overall incidence and mortality of gastric cancer in age standardised rates per 100 000 population (World population) in the European Union (EU27) is relatively low (6.5 and 4.1, respectively, for both sexes), substantial differences between countries exist. The burden remains the highest in the following among EU27 countries (age standardised rate incidence in men): Latvia (19.0), Lithuania (18.4), Portugal (18.0) and Estonia (17.5).1 Furthermore, in countries with a relatively low incidence and mortality, the burden is typically higher among vulnerable populations, including immigrants.2 3 Globally, there is an approximately 10-fold and 6-fold variability in age-standardised mortality rates in men and women, respectively. In  \nKEY MESSAGES  \n⇒ Recently, the Council of the European Union has recommended implementation of gastric cancer screening for countries or regions inside countries with a high gastric cancer incidence and death rates.  \n⇒ Several means of primary and secondary prevention are available to decrease the burden of gastric cancer; the screen and treat strategy for Helicobacter pylori (H. pylori) is the most promising one for Europe.  \n⇒ Only organised cancer screening is recommended to be used in the European Union; this includes clear definition of the intervention, target group and set up of the prog","cbCaikMZ02En6SZm","https://ap.wps.com/l/cbCaikMZ02En6SZm","pdf",385080,"English","# Abstract\n# Introduction\n# Key Messages","[{\"question\":\"What is the status of organised gastric cancer screening in Europe in 2024?\",\"answer\":\"No organised gastric cancer screening programme has been launched across Europe as of 2024.\"},{\"question\":\"Why is Helicobacter pylori screen-and-treat considered promising for Europe?\",\"answer\":\"The document states that among available strategies, the screen-and-treat approach for H. pylori is the most appropriate for Europe.\"},{\"question\":\"Which organisational aspects must be defined before full implementation?\",\"answer\":\"Implementation requires defining the target age range, test types, H. pylori eradication regimens, and surveillance strategies, among other screening set-up details.\"}]","Where are we with gastric cancer screening in Europe in 2024? | PDF",1790052972,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a6284efc1697f1ea2f488c22979ad73.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bbfe311823e7df6d4ae22848faa1f65.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a234081e768008dce5c2434297c119d.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f42fc0983736674fbd632a96f55d6aa.webp",980,1306]